Clinical Trial: A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer
Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional
Official Title:
Brief Summary: To assess the efficacy and safety of erlotinib for non-small cell lung cancer patients with leptomeningeal carcinomatosis
Detailed Summary:
Sponsor: Clinical Research Center for Solid Tumor, Korea
Current Primary Outcome: Overall survival [ Time Frame: 1 year ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Cytology negative conversion rate [ Time Frame: 1 month, 2 months, 3 months, 4 months ]
- Neurologic symptom improvement [ Time Frame: 1 month, 2 months, 3 months, 4 months ]
- Response rate (extra-cranial disease) [ Time Frame: 2 months, 4 months ]
- Response rate (brain) [ Time Frame: 2 months, 4 months ]
- Quality of life [ Time Frame: 1 month, 2 months, 3 months, 4 months ]
- Toxicities [ Time Frame: 1 month, 2 months, 3 months, 4 months ]
- Prognostic factors [ Time Frame: N-A ]
Original Secondary Outcome: Same as current
Information By: Clinical Research Center for Solid Tumor, Korea
Dates:
Date Received: January 24, 2009
Date Started: January 2009
Date Completion:
Last Updated: July 25, 2011
Last Verified: July 2011